Insights · Regulation

Maharashtra has told hospitals to stop steering patients to their own pharmacies

The order is grounded in consumer law, not drug law. That changes who can act on it, and it is not only the regulator.

Maharashtra FDA order on prescriptions and hospital-attached pharmacies

In June 2026 the Food and Drug Administration, Maharashtra, issued an order under reference FDA-13014(11)/5/2026-DRUG, signed by Commissioner Tukaram Mundhe. It says four things.

Prescriptions must be handed directly to the patient or their relatives. Hospitals must not compel purchase from an attached pharmacy. Patients must be told they may buy from any licensed vendor. And notices to that effect must be displayed, in Marathi and English.

It is addressed to all hospitals in the state, public and private, to hospital-affiliated pharmacies, and to medical practitioners. There is no bed-count threshold and no carve-out.

The legal basis is the Consumer Protection Act, not the Drugs Act

The order grounds itself in section 2(47) of the Consumer Protection Act 2019 — unfair trade practice — and in Article 21, with the drug law referenced alongside. That matters because it means the exposure is not only an FDA inspection. A patient can take an unfair trade practice to a consumer forum, and the order is the document they will attach.

Two things it does not say

It is worth being precise, because this order has been described loosely.

It contains no consent mechanism. Some coverage described hospitals as needing explicit patient consent before routing a prescription to an in-house pharmacy. The order does not create a consent route. It is framed as non-compulsion and patient choice, which is a stronger requirement, not a procedural one you can paper over with a signature.

And it names no penalty amount. The operative wording is that appropriate legal action will be taken against the institution concerned. Treat the absence of a figure as uncertainty, not as reassurance.

Why this is a bigger deal than it reads

Hospital pharmacy is among the highest-contribution lines in an Indian private hospital, and in many mid-sized hospitals it quietly subsidises the clinical lines that do not cover their cost. An order that formally decouples the prescription from the pharmacy counter goes at that directly.

It does not ban the in-house pharmacy or cap its margin. What it removes is captivity. A discharge pharmacy that keeps its volume because it is convenient, well stocked and fairly priced will keep most of it. One that keeps its volume because the prescription never physically reaches the patient will not.

What this means for your hospital

If you operate in Maharashtra, three things are due now. Put the bilingual notice up, because it is the visible compliance item and the one an inspector will photograph first. Change the discharge process so the prescription is handed over as a matter of course rather than walked to the counter. And brief the nursing and billing staff, since the practice this targets is usually habit rather than policy, and habit is not fixed by a circular pinned in the administrator's office.

If you operate elsewhere, do the arithmetic anyway. Work out what share of your contribution comes from discharge pharmacy on captive volume rather than on price and availability. That is the number at risk if another state follows, and it is worth knowing before you are asked.

We have found no evidence that any other state has issued a similar order, and no evidence of a hospital association challenging this one. Both may simply be unreported.

Sources

Note on dating: the order carries no printed date. Business Standard, reporting on 14 June 2026, dates the directive 12 June; the FDA published the document on 16 June 2026. Since the order itself is undated we describe it as a June 2026 order rather than assigning a day.

If pharmacy is carrying your margin, you need a second engine.

We map where your contribution actually comes from and build the case mix, tariff and cost changes that reduce single-line dependence.

More from Insights

WhatsApp us Call Email